Pharvaris N.V.
NASDAQ:PHVSBiotechnology
-$0.64 today
- Market cap
- $2.21B
- Beta
- -2.33
- P/E (TTM)
- -11.0
- EPS (TTM)
- -$2.59
Volume 0.39M
Average 0.31M
PHVS Cash & Equivalents
Cash on hand and highly liquid investments that can be converted to cash almost immediately.
Pharvaris N.V.NASDAQ: PHVS
Cash & Equivalents · Q3 FY2026 · quarter ended Sep 2026
Cash & equivalents falls 14.1% from a year ago
Cash & equivalents stood at €282.73M at the end of Q3 FY2026, down 14.1% from a year earlier and down 11.2% from the prior quarter. Over 3 fiscal years it compounded at +21.7% a year.
Context
- Cash & equivalents amounted to 95.8% of total assets at the end of Q3 FY2026, down 1.3 pp from a year earlier.
- Cash & equivalents increased in 2 of the last 3 fiscal years.
What to watch
Whether cash & equivalents keeps falling in the next quarterly balance sheet after a -14.1% change from a year earlier.
Sources:Balance SheetText generated from reported figures; not investment advice.
Cash & Equivalents history
EUR · from the balance sheet
- Latest · FY2025
- 291.68M EUR
- Year-over-year change
- +3.9%
- 4-year CAGR
- +8.6%
| Period | Period end | Cash & Equivalents | YoY change |
|---|---|---|---|
| FY2025 | 2025-12-31 | 291.68M | +3.9% |
| FY2024 | 2024-12-31 | 280.73M | -28.2% |
| FY2023 | 2023-12-31 | 391.23M | +141.7% |
| FY2022 | 2022-12-31 | 161.84M | -22.7% |
| FY2021 | 2021-12-31 | 209.35M | — |
Cash & Equivalents vs competitors
How PHVS compares with its peers on the latest reported figures
- Peers report in different currencies, so cash & equivalents is compared through growth and share of total assets rather than absolute size.
- Its year-over-year change of -14.1% is the lowest of 7, against a peer median of +43.7%.
- Cash & equivalents amounts to 95.8% of total assets for PHVS, versus a peer median of 12.7%.
| Company | Period | Latest balance | YoY | 3-year CAGR | % of assets |
|---|---|---|---|---|---|
| Sep 2026 | $736.01B USD | +58775.5% | +21.9% | 6.4% | |
| Sep 2026 | €282.73M EUR | -14.1% | +21.7% | 95.8% | |
| Jun 2026 | $154.97M USD | +76.0% | -33.5% | 27.8% | |
| Sep 2026 | $123.54M USD | +11.4% | +14.7% | 14.6% | |
| Mar 2026 | $53.1M USD | -11.6% | -11.0% | 10.9% | |
| Jun 2026 | $48.88M USD | -0.5% | +101.3% | 9.2% | |
| Mar 2026 | $41.3M USD | +179.4% | -18.0% | 75.8% | |
| Peer median (excluding PHVS) | — | +43.7% | +1.8% | 12.7% | |
Competitors are the stored peer set for PHVS. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.
Balance Sheet
Metric | FY2021 Dec 2021 | FY2022 Dec 2022 | FY2023 Dec 2023 | FY2024 Dec 2024 | FY2025 Dec 2025 |
|---|---|---|---|---|---|
| Cash & Equivalents | 209.35M | 161.84M | 391.23M | 280.73M | 291.68M |
| Short-term Investments | 0 | 0 | 0 | 0 | 0 |
| Net Receivables | 700.08K | 382.47K | 1.04M | 2.94M | 4.55M |
| Inventory | 0 | 4.04M | 0 | 0 | 0 |
| Other Current Assets | 5.7K | 582.59K | 620.82K | 0 | 0 |
| Total Current Assets | 211.57M | 166.85M | 397.85M | 289.42M | 299.17M |
| Property, Plant & Equipment (Net) | 351.35K | 626.44K | 455.57K | 1.48M | 1.4M |
| Goodwill | 0 | 0 | 0 | 0 | 0 |
| Intangible Assets | 0 | 0 | 0 | 0 | 0 |
| Long-term Investments | 0 | 0 | 0 | 0 | 0 |
| Tax Assets | 172.05K | 259.8K | 387.53K | 474.35K | 887.35K |
| Other Non-current Assets | 0 | 0 | 0 | 0 | 0 |
| Total Non-current Assets | 523.4K | 886.24K | 843.1K | 1.96M | 2.29M |
| Total Assets | 212.09M | 167.73M | 398.69M | 291.37M | 301.45M |
| Account Payables | 2.13M | 5.98M | 2.91M | 4.56M | 5.11M |
| Short-term Debt | 0 | 0 | 0 | 0 | 0 |
| Tax Payables | 491.22K | 1.17M | 430.28K | 601.25K | 941.21K |
| Deferred Revenue | 0 | 0 | 0 | 0 | 0 |
| Other Current Liabilities | 1.46M | 461.3K | 429.92K | 7.83M | 11.43M |
| Total Current Liabilities | 6.99M | 18.22M | 14.6M | 22.97M | 29.6M |
| Long-term Debt | 0 | 0 | 0 | 0 | 0 |
| Deferred Tax Liabilities | 0 | 0 | 0 | 0 | 0 |
| Deferred Revenue (Non-current) | 0 | 0 | 0 | 0 | 0 |
| Other Non-current Liabilities | (1) | 0 | 0 | 0 | 0 |
| Total Non-current Liabilities | 150.75K | 249.42K | 43.56K | 639.04K | 576.59K |
| Total Liabilities | 7.14M | 18.47M | 14.65M | 23.61M | 30.18M |
| Common Stock | 3.98M | 4.06M | 6.27M | 6.53M | 7.83M |
| Retained Earnings | (87.57M) | (164.19M) | (265.92M) | (402.26M) | (579.6M) |
| Accumulated OCI | 9.8M | 20.21M | 27.88M | 39.85M | 50.5M |
| Other Stockholders Equity | 0 | 0 | 0 | 0 | 0 |
| Minority Interest | 0 | 0 | 0 | 0 | 0 |
| Total Equity | 204.95M | 149.26M | 384.05M | 267.76M | 271.27M |
| Total Debt | 250.18K | 436.82K | 238.91K | 861.47K | 776.8K |
| Net Debt | (209.1M) | (161.4M) | (390.99M) | (279.87M) | (290.9M) |
Pharvaris N.V.
NASDAQ:PHVS
Intrinsic Alpha fair value
Locked
Current Price
$31.55
Unlock the intrinsic value to see where the current price sits on the valuation runway.
Valuation runway
LockedGet the intrinsic value and margin of safety with a free account.
Continue the stock analysis
Jump to another research area for this company.